Slide 1: Fast-Tracking the Future of Cell Therapy
Fast-Tracking the Future of Cell Therapy: Advancing Biologic-Scale Allogeneic CAR T Toward the Finish Line August 2026 1
Slide 2: Legal Disclaimers
Legal Disclaimers This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward- looking statements. Words such as “anticipate,” “beli
Slide 3: Redefining CAR T: The Five Key Dimensions that May Unlock its Full Potential
Redefining CAR T: The Five Key Dimensions that May Unlock its Full Potential Efficacy Transform patient care: one- time dosing to prevent disease recurrence Allogeneic CAR T Simplicity Reduce the treatment Safety has the Potential to Support outpatient burden: no apheresis or cell processing managem
Slide 4: Three Purpose-Built Programs Designed to Redefine Patient Care
Three Purpose-Built Programs Designed to Redefine Patient Care… Changing the Standard of Care Cema-cel ALPHA3 pivotal RCT in 1L consolidation LBCL w/potential to improve cure rates (CD19) Interim futility analysis April 2026; FDA RMAT and Fast Track designations; next program update tied to the inte
Slide 5: Remove Barriers to Unlock Broader CAR T Market Potential
…and Remove Barriers to Unlock Broader CAR T Market Potential ALPHA3 RESOLUTION TRAVERSE cema-cel (CD19) ALLO-329 (CD19/CD70) ALLO-316 (CD70) ~$5B >$15B >$3.5B Assumes ~15K US/EU/UK patients Based on US prevalence (~500K) Assumes ~9K patients worldwide with treated in LBCL 1L consolidation among rhe
Slide 6: Cema-Cel: The ALPHA3 Pivotal Study
Cema-Cel: The ALPHA3 Pivotal Study Giving LBCL Patients a Second Chance at First-Line Success 6
Slide 7: MRD Is Emerging as the Most Reliable Predictor of Relapse in LBCL
MRD Is Emerging as the Most Reliable Predictor of Relapse in LBCL Patients who clear MRD at the end of 1L treatment are at low risk of recurrence1-4 Patients who do not clear MRD are at high risk of relapse 1-4 A paradigm shift in LBCL management: Can we safely and effectively treat patients who rem
Slide 8: ALPHA3: Disrupting the Course of Disease, Not How Clinicians Practice
ALPHA3: Disrupting the Course of Disease, Not How Clinicians Practice Current Standard of Care Potential for a New Standard of Care* 1L Treatment 1L Treatment ctDNA-based MRD Test + cema-cel Consolidation "Watch and Wait" Until Disease Recurrence Reduce Risk of Recurrence Up to 30% Require 2L Treatm
Slide 9: Pivotal ALPHA3 Trial Poised for Multiple Program-Defining Readouts
Pivotal ALPHA3 Trial Poised for Multiple Program-Defining Readouts 1L LBCL 1:1 Consolidation Randomization cema-cel Interim Primary Interim Randomization EFS EFS Futility Following Analysis Analysis MRD Analysis Screening Expected Expected April 2026* Mid-2027 Mid-2028 Observation Cema-cel administe
Slide 10: ALPHA3 Interim Futility Analysis: MRD Clearance Exceeded Benchmark
ALPHA3 Interim Futility Analysis: Absolute Difference in MRD Clearance Exceeded 25-30% Benchmark MRD Clearance Rate Change in ctDNA At last assessment at Day 45 (median) 58.3% (n=7/12) +26.6% 41.6% Absolute difference in MRD clearance MRD Reduction Occurred Rapidly 16.7% Following Cema-cel (n=2/12)
Slide 11: Literature Supports 25-30% MRD Clearance Difference as Potentially Transformative
Literature Supports 25-30% MRD Clearance Difference as Potentially Transformative Study Study Endpoint Clinical Outcome* MRD Clearance Breyanzi compared to ASCT Reduced risk of EFS events by Breyanzi in 2L DLBCL w/CAR T in (TRANSFORM)1,2 Improved MRD clearance4 by 63% r/r DLBCL 24% (HR = 0.375) MRD
Slide 12: MRD Clearance Differential Post-CAR T Correlates With Durable EFS Benefit
MRD Clearance Differential Post-CAR T Correlates With Durable EFS Benefit MRD Clearance Difference = 24% 3-year EFS Rate2 Liso cel = 45.8% SOC = 19.1% 1Stepan, L., et al. (2024). Circulating tumor DNA (ctDNA) as an early outcome predictor in patients with second-line large B-cell lymphoma after liso
Slide 13: ALPHA3 Interim: Well-Tolerated Safety Results Support Outpatient and Community Use
ALPHA3 Interim Futility Analysis: Well-Tolerated Interim Safety Results Support Use in Outpatient and Community Setting Cema-cel Arm (N=12) Observation Arm (N=12) TEAEs of Special Interest n (%) n (%) CRS (Any Grade)1 0 - ICANS (Any Grade)1 0 - GvHD (Any Grade) 0 - Infection2 2 (16.7%) 2 (16.7%) Inf
Slide 14: ALPHA3 Expands CAR T into Community Settings
ALPHA3 Expands CAR T into Community Settings 80+ Active Sites Majority in US; Additional in Canada, South Korea & Australia ~33% of screening activity and cema- cel infusions at the time of the interim futility analysis were conducted at community cancer centers, including at sites new to CAR T ~100
Slide 15: ALPHA3 Designed to Expand CAR T Access Where Patients Are Treated
ALPHA3 Designed to Expand CAR T Access Where Patients Are Treated Current State: Limited CAR T Access • Only ~15% of 2L+ LBCL patients receiving CAR T1 • Access limited to ~200 Authorized Treatment ALPHA3 Designed to Enable Centers in U.S., mostly at academic centers Cema-cel Commercialization by Ad
Slide 16: What Could Drive CAR T Adoption in 1L Consolidation
What Could Drive CAR T Adoption in 1L Consolidation Confidence in Outcomes • MRD-guided approach broadly embraced and viewed as highly differentiated vs other studies • Efficacy seen as clinically meaningful Confidence in Delivery With CAR T, Physicians Recognize that Efficacy Alone is Not Enough –
Slide 17: Market Insights: Physicians Are Ready to Act Earlier If the Therapy Fits
Market Insights: Physicians Are Ready to Act Earlier If the Therapy “Fits” Cema-cel 1L LBCL Consolidation Target Product Profile Reactions1 Physician Projections MRD Testing Market Share ~75 - 80% ~50 - 70% Patients who would receive MRD MRD+ patients who would receive testing at end of 1L therapy c
Slide 18: Projected ~$5B 1L Consolidation CAR T Market Opportunity
Projected ~$5B 1L Consolidation CAR T Market Opportunity 1L Consolidation Potential Market Opportunity Sizing1 US EU5 1L Drug-Treated Patients ~34,000 ~31,000 % CR/PR Who Will Later Relapse w/MRD-Positivity ~30%* % MRD Tested ~75% Potential US+EU5 >14,700 Patients/Year Addressable Patients2 ~$5B Rev
Slide 19: Path to Pivotal EFS Data in Mid-2028
Path to Pivotal EFS Data in Mid-2028 Key Anticipated Activities and Catalysts 2026 2027 2028 • Mid-year: Interim EFS • Mid-year: Primary EFS • Continued Site Expansion in analysis* analysis* U.S. and ex-US regions • End of year: Enrollment • Powered to Detect a 50% completed (n=220) Reduction in the
Slide 20: Supercharging AlloCAR T Products
Supercharging AlloCAR T Products ALLO-329 ALLO-316 Dagger® Technology: A Potentially Transformative Solution to Allo-Rejection 20
Slide 21: Dagger Technology: A Potentially Transformative Solution to Allo-Rejection
Dagger® Technology: A Potentially Transformative Solution to Allo-Rejection The Insights Driving a New Approach to Mitigate Allo-Rejection • Host allo-reactive T cells drive allogeneic CAR T rejection • CD70⁺ activated T cells are the key mediators of host allo-reactivity¹ The Proprietary Dagger® Me
Slide 22: Dagger: Clinical Data Demonstrate Robust CAR T Expansion
Dagger®: Clinical Data Demonstrate Robust CAR T Expansion Product / Cmax AUC0-28 Clinical Validation of Dagger® Candidate Cell Dose copies/µg day*copies/µg Technology • Translational data from ALLO-316 ALLO-316 80 M 64,647 620,910 demonstrated robust CAR T expansion that matches or exceeds autologou
Slide 23: ALLO-329: Purposefully Designed for Autoimmune Disease & Patient Access
ALLO-329: Purposefully Designed for Autoimmune Disease & Patient Access ALLO-329 Targets Dual Pathogenic Immune Cell Pathways Dual CD19/CD70 CAR to enable both disease • Designed to deplete B cells and auto-reactive CD70+ T cells control and immune conditioning • Potential for minimized or no lympho
Slide 24: RESOLUTION: A Platform-Defining PoC for an AlloCAR T in Autoimmune Disease
RESOLUTION: A Platform-Defining PoC for an AlloCAR T in Autoimmune Disease RESOLUTION Protocol Schema of Parallel Dose Escalation With or Without Lymphodepletion DL1 DL2 DL3 DL4 Next Key Milestone with Cy only with Cy only with Cy only with Cy only Q4 2026: Program Update After 1 patient DL1 DL2 DL3
Slide 25: ALLO-316: Path to Addressing Unmet Need in Solid Tumors
ALLO-316: Path to Addressing Unmet Need in Solid Tumors Encouraging Activity In Solid Tumor Global Market Opportunity High Unmet Need in r/r RCC • Standard outcomes in r/r RCC are poor: ~20% ORR and <6mo mPFS1a, 1b 31% ORR in r/r RCC with high CD70+ expression2 • All responders progression-free at t
Slide 26: ALLO-316 Demonstrates a CAR T Can Deliver Durable Benefit in Solid Tumors
ALLO-316 Demonstrates a CAR T Can Deliver Durable Benefit in Solid Tumors Promising Durable Responses in Refractory Patients Who Had Exhausted All Approved Therapies Srour, et al, “Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the P
Slide 27: Allogene: Fast-Tracking the Future of Cell Therapy
Allogene: Fast-Tracking the Future of Cell Therapy AlloCAR T Platform: Potential to Deliver Near-Term Milestones Across All 5 Key Dimensions (Safety, Speed, Scalability, Simplicity & Efficacy) Cema-cel / ALPHA3 • Mid-2027: Program Update 3 Programs Poised to Unlock Multi- Tied to Interim EFS analysi
Slide 28: Fast-Tracking the Future of Cell Therapy
Fast-Tracking the Future of Cell Therapy: Advancing Biologic-Scale Allogeneic CAR T Toward the Finish Line Allogene’s investigational AlloCAR T oncology product candidates utilize the TALEN® gene-editing technology. Cemacabtagene ansegedleucel (cema-cel) was developed based on an exclusive worldwide
Slide 29: Pipeline Designed to Maximize Greatest Opportunity
Pipeline Designed to Maximize Greatest Opportunity 1Phase 2 designed to be registrational 29
Slide 30: The Right Product: Foundational Ph1 Cema-cel Data Paves the Way for ALPHA3
The Right Product: Foundational Ph1 Cema-cel Data Paves the Way for ALPHA3 Median Time From Enrollment to Treatment = 2 days Patients Who Received KYMRIAH®1 YESCARTA®2 BREYANZI®3 3L Relapsed/Refractory LBCL All Patients (n=33) Selected Ph2 Dosea (n=12) Phase 2 Pivotal Phase 2 Pivotal Phase 2 Pivotal
Slide 31: Subgroup Analyses and Durability Show Proof of Concept for Cema-cel in ALPHA3
Subgroup Analyses and Durability Show Proof of Concept for Cema-cel in ALPHA3 ALPHA/ALPHA2 Ph1 Data Published in Journal of Clinical Oncology High CR Rates In Subgroups Most Similar to Expected Ongoing Responses >4 Years in Complete Responders ALPHA3 Population • Patients w/normal LDH: 82% (9/11) •
Slide 32: Opportunity to Leapfrog Competition with an Alternative to Watch and Wait
Opportunity to Leapfrog Competition with an Alternative to “Watch and Wait” Treat Patients Earlier, Where They Are, and With a Simplified, One-Time Therapy MRD- Remission Standard 1L End of Therapy Evaluation ~60% ctDNA-based MRD Test Cured Future State Responding Complete Previously ”Watch and Wait
Slide 33: ALPHA3: Designed to Dramatically Transform the LBCL Market
ALPHA3: Designed to Dramatically Transform the LBCL Market Projected US+EU5 CAR T Market Size in LBCL by Line of Therapy Market Split: US ~ 2/3, EU5 ~ 1/3 ~$7B Estimated US+EU5 CAR T Net Sales ($B) 1L Consolidation ~14,700 ~$3.5B Potential Patients/Year* Opportunity ~$2.5B ~$5B* 2L 2L ~$1B 2L 3L+ 3L
Slide 34: ALPHA3 Interim Futility Analysis: Enrolled Patients Had Aggressive Disease Characteristics
ALPHA3 Interim Futility Analysis: Enrolled Patients Had Aggressive Disease Characteristics At Original Diagnosis Cema-cel Arm (N=12) Observation Arm (N=12) n (%) n (%) History of Bone Marrow Involvement 4 (33.3%) 3 (25%) Disease Stage I - II 0 2 (16.7%) III - IV 12 (100%) 10 (83.3%) IPI Score 0 to 1
Slide 35: ALPHA3 Interim: First-Line Regimens and PET Response to the 1L Regimen
ALPHA3 Interim Futility Analysis: First-Line Regimens and PET Response to the 1L Regimen Cema-cel Arm (N=12) Observation Arm (N=12) n (%) n (%) First-Line Treatment R-CHOP 2 (16.7%) 3 (25.0%) R-Pola-CHP 2 (16.7%) 2 (16.7%) DA-EPOCH-R 7 (58.3%) 5 (41.7%) R-miniCHOP 1 ( 8.3%) 2 (16.7%) Most Recent PET
Slide 36: TRAVERSE Addressable Population Creates a >$3.5B Opportunity
TRAVERSE Addressable Population Creates a >$3.5B Opportunity 3L+ ccRCC Potential Market Opportunity Sizing US Ex-US 3L+ Drug-Treated Patients1 ~7,500 ~7,600 % Prior-ICI/TKI ~100% % CD70+2 ~80% % CD70 ~75% TPS ≥ 50%2 Potentially Addressable WW ~9,000 Patients/Year Market Opportunity3 >$3.5B Revenue P